Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 19, 2026 at the company’s San Diego headquarters. Stockholders of record at the close of business on March 23, 2026, when 92,369,812 common shares were outstanding, may vote.
Key items include electing ten directors for one-year terms, approving an amendment to the 2018 Equity Incentive Plan to add 3,000,000 shares for equity awards, advisory approval of executive compensation and the preferred frequency of say‑on‑pay votes, and ratification of Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
The proxy also details board independence, committee responsibilities, board risk oversight (including cybersecurity and ESG), and significant stockholder and management ownership levels, such as several institutions each holding more than 5% of outstanding shares as of March 2, 2026.
Travere Therapeutics CEO Eric M. Dube exercised stock options covering 60,000 shares of common stock at $15.46 per share on April 1, 2026, then sold the same 60,000 shares in the open market.
The sales were split between 34,902 shares at $30.55 and 25,098 shares at $31.46, executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on June 16, 2025. After these transactions, Dube directly holds 432,886 shares of Travere common stock.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed exercised employee stock options and sold shares in a planned transaction. She exercised options for 10,000 shares of common stock at $15.46 per share and then sold 10,000 shares at $30.00 per share on the same day. After these transactions, she directly holds 105,211 shares of Travere Therapeutics common stock. The filing notes the sale was made under a written plan adopted on June 16, 2025 that meets Rule 10b5-1(c) requirements, and that the underlying stock option grant from January 31, 2020 is fully vested and exercisable.
TVTX filed a Form 144 disclosing the intended sale of 60,000 shares of Common Stock on 04/01/2026. The filing lists the sale method as cash and records several prior dispositions in the past three months: 8,135; 51,865; 100,087; and 60,000 shares on specified dates.
Elizabeth Reed reported the proposed sale of 10,000 shares of Common Stock under Form 144, linked to a stock option exercise dated 04/01/2026. The filing lists multiple earlier dispositions in 2026: 10,000 shares on 03/16/2026 for $280,861.00, 10,000 on 02/17/2026 for $278,317.00, and other smaller sales in February and January.
Travere Therapeutics Inc ownership filing shows The Vanguard Group reports 0 shares beneficially owned of Common Stock and 0% of the class. The amendment explains an internal realignment effective January 12, 2026, causing certain Vanguard subsidiaries and divisions to report holdings separately in reliance on SEC Release No. 34-39538.
Travere Therapeutics’ Chief Legal Officer Elizabeth E. Reed exercised employee stock options to acquire 10,000 shares of common stock at an exercise price of $19.08 per share, then sold 10,000 shares at a weighted average price of $28.0861 per share.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025, tied to a stock option grant expiring on January 4, 2027. Following these transactions, Reed holds 105,211 shares of Travere Therapeutics common stock directly.
Elizabeth Reed submitted a Form 144 indicating a proposed sale of $278,861.00 worth of Common stock via a stock option exercise for 10,000 shares on 03/16/2026. The filing also lists prior dispositions by Ms. Reed in the past three months: $278,317.00 for 10,000 shares on 02/17/2026, $96,360.09 for 2,994 shares on 02/04/2026, $230,463.88 for 7,175 shares on 02/03/2026, and $273,420.00 for 10,000 shares on 01/20/2026.
Travere Therapeutics, Inc. CEO Eric M. Dube exercised stock options for 60,000 shares on February 20, 2026, converting an employee stock option into common stock at an exercise price of $15.4600 per share. He then sold 60,000 common shares in an open-market transaction at a weighted average price of $30.0961, under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following these transactions, his directly held common stock position was 432,886 shares.